| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses, net of government assistance | 568 | 955 | ||
| General and administrative expenses | 1,961 | 2,135 | ||
| Loss from operating activities | -2,529 | -3,090 | ||
| Foreign exchange (loss) gain | -8 | 10 | ||
| Change in fair value of derivative warrant liabilities | -1,427 | 487 | ||
| Interest and other income, net | 172 | 205 | ||
| Total other income, net | 1,591 | -272 | ||
| Loss before income tax recovery | -938 | -3,362 | ||
| Income tax benefit | 0 | 0 | ||
| Net loss | -938 | -3,362 | ||
| Basic loss per share (in dollars per share) | -0.06 | -0.21 | ||
| Diluted loss per share (in dollars per share) | -0.06 | -0.21 | ||
| Weighted average number of shares outstanding, diluted (in shares) | 15,924,522 | 15,924,522 | ||
| Weighted average number of shares outstanding. basic (in shares) | 15,924,522 | 15,924,522 | ||
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)